As I see it

Share this article:
Federal agencies like FDA are moving creakily, if at all, to implement the “open government” mandate from the Obama administration as old practices continue and in some cases solidify. A year and a half after the president issued his mandate, little has changed at FDA apart from a new “FDA Basics” web page which has information the agency thinks people should know, and recommendations on improved document availability from an internal FDA Transparency Task Force.

Meanwhile, instantly do-able administrative-type reforms, like re-opening the agency's staff to direct media contact, as in decades past, have been ignored. Now reporters are restricted to press offices which shield agency employees from the media's inquiring minds—and where public information can be given the “spin” the government wants it to have.

The main problem is agency “culture”—those long-established practices that make career civil servants comfortable in their various assignments. The old system of reporters calling or emailing at will made some FDAers uncomfortable, although most saw it as a cost of their service in the world's most open government. All that changed after the 1996 Oklahoma City bombing was that metal detectors were installed in all federal buildings. The development of confidential sources unknown to management became impossible. Worse, press officers started monitoring and taping communications.

In May, the internal FDA Transparency Task Force rejected a request from journalism groups to restore the prior media access system. It said it would strive to make the present system work better.

For government managers, controlling the media is too powerful a tool to voluntarily surrender.

James G. Dickinson is editor of Dickinson's FDA Webview (

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in As I See It

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications